Tuesday, April 16, 2024
4/16/2024
Project Summary The oncoprotein interferon regulatory factor 4 (IRF4) is a lymphocyte-specific transcription factor that is frequently overexpressed and mutated in hematological malignancies, including Epstein-Barr Virus (EBV)- associated, AIDS-related lymphomas (ARLs), which are the leading cause of HIV/AIDS-related cancer deaths even in the current antiretroviral therapy (ART) era. However, the precise mechanisms underlying IRF4- mediated oncogenesis is poorly understood. We have shown that IRF4 is critical for survival of virus (EBV, HTLV1)-transformed cells, and its depletion causes apoptosis, at least through transcriptional upregulation of the oncogenic miRNA miR-155 and the adaptor protein LIMD1 that in turn participates in EBV Latent Transmembrane Protein 1 (LMP1) signal transduction and is required for oxidative stress-induced autophagy, amongst many other IRF4 transcriptional targets. We have also shown that IRF4 is activated through c-Src- mediated tyrosine phosphorylation downstream of LMP1 signaling, in EBV-transformed cells, with the aid of several unbiased “state-of-the-art” high throughput techniques including phosphotyrosine proteomics, and ubiquitinomics. Furthermore, we have collected several lines of evidence in these studies showing that IRF4 is ubiquitinated with K63-linked ubiquitin chains, and that apoptosis induces a smaller size of IRF4, which may be a caspase-cleaved product and may represent a dominant negative mutant lacking the DNA-binding activity. Correspondingly, a potential caspase-cleavage site proximal to C-terminus of its DNA-binding domain was identified. Thus, the proposed study aims to test two hypotheses that: and converts IRF4 to a dominant-negative pro-apoptotic mutant; and 1) 2) caspase-3 cleaves IRF4 in apoptosis LMP1 signaling stimulates K63-linked ubiquitination of IRF4 that promotes IRF4 transcriptional activity. These studies will provide novel mechanistic insights into IRF4 posttranslational modifications in regulation of its activity and functions in virus-associated hematological malignancies. Findings from these studies and future long-term pursuits will shed new light on the importance of IRF4 in viral oncogenesis, and may identify the LMP1-IRF4 regulatory network as a potential therapeutic target for treating EBV-associated, AIDS-related hematological malignancies.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
